Evidera
Sara Angleman is a research scientist with extensive experience in epidemiology and real-world evidence. Sara has worked in various roles at companies like Evidera, ICON plc, and IQVIA. Sara also has experience as a researcher at Karolinska Institutet and as a PhD student at The National Institutes of Health through the OxCam program. Sara's educational background includes a Bachelor of Science in Biochemistry and Molecular Biology from the University of Maryland Baltimore County, and a PhD in Epidemiology from the University of Cambridge.
This person is not in any offices
Evidera
1 followers
Evidera is a business within Pharmaceutical Product Development, LLC, (PPD) a leading global contract research organization (CRO), and is the preeminent provider of evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products from early development through loss of exclusivity. We provide integrated scientific expertise and global operational capabilities to help you generate the evidence needed to optimize the market access and commercial potential of your products. Evidera was acquired by PPD in 2016 and originally created in 2013 as an independent company under the ownership of Symphony Technology Group following the acquisition of long-standing health economics, outcomes research, market access, epidemiology, and data analytics practices from United BioSource Corporation (UBC). Evidera has over 30 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes.